In centralized procurement, products that adhere to rigorous quality systems, leverage economies of scale, and have gained clinical recognition and widespread adoption are anticipated to uphold or extend their market share. Furthermore, innovative drugs continue to enjoy robust policy support, evidenced by a success rate exceeding 90% in the 2024 medical insurance negotiations, with domestically produced drugs comprising over 70% of successful cases. The introduction of commercial insurance policies has also broadened the payment options for innovative drugs. The government's "Several Measures to Support the High-Quality Development of Innovative Drugs" provides a comprehensive framework encompassing the entire lifecycle of innovative drugs, from research and development to reimbursement. Additionally, domestic innovative pharmaceutical companies are witnessing a steady rise in international competitiveness, fueled by the rapid advancement of new technologies. As a result, innovative drugs and their respective pharmaceutical companies remain promising investments for the future.